EC Paediatrics

A dietary supplement (DS) “Atherophyton” is a herbal remedy obtained by an innovative method of cryo-technological grinding and containing medicinal raw materials from 14 plants common in Ukraine. The aim of this study was to investigate the effect of the DS “Atherophyton” on the morphological state of the pancreas under conditions of experimental metabolic syndrome (EMS) in Syrian golden hamsters. EMS in Syrian golden hamsters was induced by feeding animals for 24 days on a diet enriched with fructose (60% of the total daily diet). The studied DS “Atherophyton” and comparison drugs: metformin and phyto-composition were administered intragastrical starting from day 15 of EMS modeling for 10 days. Prolonged consumption of carbohydrate-rich (fructose) food by Syrian golden hamsters led to distinct changes in the insular apparatus: a decrease in the total number of pancreatic islets, a percentage redistribution of islets in size, dystrophic and destructive changes in them, and the devastation of some islets. Against the background of EMS, the studied DS “Atherophyton” sufficiently contributed to the improvement of the morphological state of the pancreatic incretory apparatus in all parameters and was superior to the comparison drug: phyto-composition contend phyto-composition and inferior to metformin in terms of protective effect.

 Keywords: Phytotherapy; Polypharmaceutical Composition; Cryo-Technology; Experimental Metabolic Syndrome; Pancreas; Syrian Golden Hamsters

1. Badawy M., et al. “Metabolic syndrome: imaging features and clinical outcomes”. British Journal of Radiology 1154 (2024): 292-305.
2. Matsui M., et al. “Metabolic syndrome and somatic composition: A large cross-sectional analysis”. In Vivo1 (2025): 381-389.
3. Wentzel A., et al. “Prevalence of metabolic syndrome in children and adolescents with obesity: a systematic review and meta-analysis”. Obesity (Silver Spring)1 (2025): 12-32.
4. Ambroselli D., et al. “New advances in metabolic syndrome, from prevention to treatment: the role of diet and food”. Nutrients3 (2023): 640.
5. Madan K., et al. “Metabolic syndrome: The constellation of co-morbidities, a global threat”. Endocrine, Metabolic and Immune Disorders - Drug Targets12 (2023): 1491-1504.
6. Angelico F., et al. “Diet and metabolic syndrome: a narrative review”. Internal and Emergency Medicine 4 (2023): 1007-1017.
7. Yang M., et al. “Myostatin: a potential therapeutic target for metabolic syndrome”. Frontiers in Endocrinology (Lausanne) 14 (2023): 1181913.
8. Xu Z., et al. “Oxidative balance score was negatively associated with the risk of metabolic syndrome, metabolic syndrome severity, and all-cause mortality of patients with metabolic syndrome”. Frontiers in Endocrinology (Lausanne) 14 (2024): 1233145.
9. Wang S., et al. “Natural polyphenols: a potential prevention and treatment strategy for metabolic syndrome”. Food and Function 19 (2022): 9734-9753.
10. Zhang S., et al. “Natural polyphenols in metabolic syndrome: Protective mechanisms and clinical applications”. International Journal of Molecular Sciences 11 (2021): 6110.
11. Iqbal I., et al. “Plant polyphenols and their potential benefits on cardiovascular health: a review”. Molecules 17 (2023): 6403.
12. Rana A., et al. “Health benefits of polyphenols: A concise review”. Journal of Food Biochemistry 10 (2022): e14264.
13. Rudrapal M., et al. “Dietary polyphenols and their role in oxidative stress-induced human diseases: insights into protective effects, antioxidant potentials and mechanism(s) of action”. Frontiers in Pharmacology 13 (2022): 806470.
14. Guo J., et al. “Protective effects and molecular mechanisms of tea polyphenols on cardiovascular diseases”. Frontiers in Nutrition 10 (2023): 1202378.
15. Amiot MJ., et al. “Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review”. Obesity Reviews 7 (2016): 573-586.
16. Research and Production Pharmaceutical Company "AIM".
17. Galchynetska YL., et al. “Method for preparing a mixture of plant materials”. Patent of Ukraine No.19415. State system of legal protection of intellectual property in Ukraine (2006).
18. Taghibiglou C., et al. “Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular Apob degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model”. Journal of Biological Chemistry 12 (2000): 8416-8425.
19. Kalko K., et al. “Prospects of complex pharmaceutical composition application for pharmacological correction of metabolic syndrome”. Ceska a Slovenska Farmacie 6 (2024): 288-296.
20. Kalko K., et al. “The Influence of atherophyton on the development of low-grade inflammation in experimental metabolic syndrome in Syrian golden hamsters”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 4 (2024): 454-458.
21. Rybolovlev YuR., et al. “Predictive evaluation of safety of substances for humans by constants of their biological activity. Toxicological aspects of safety of finished dosage forms”. Abstract of scientific conference Moscow (1981): 9-10.
22. Adeyemi DO., et al. “Histomorphological and morphometric studies of the pancreatic islet cells of diabetic rats treated with extracts of Annona muricata”. Folia Morphologica (Warsz)2 (2010): 92-100.
23. Gurina TS., et al. “Histology, Staining”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2024): 32491595.
24. Mata DA., et al. “Statistical methods in experimental pathology: a review and primer”. American Journal of Pathology 5 (2021): 784-794.
25. Nesterok YA. “Morphological study of the triad of organs - liver, pancreas and duodenum - in experimental opisthorchiasis”. PhD thesis (2013): 24.
26. Maiztegui B., et al. “Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats”. Clinical Science (London)2 (2011): 73-80.
27. Bartley C., et al. “Chronic fructose renders pancreatic β-cells hyper-responsive to glucose-stimulated insulin secretion through extracellular ATP signaling”. American Journal of Physiology Endocrinology and Metabolism 1 (2019): E25-E41.
28. Araújo TG., et al. “Insulin-resistance-associated compensatory mechanisms of pancreatic beta cells: a current opinion”. Frontiers in Endocrinology 4 (2013): 146.